Boston Therapeutics, Inc.
BTHE · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $9,169 | $9,169 | $6,900 | $1,111 |
| - Cash | $2,384 | $3,960 | $47 | $7 |
| + Debt | $548 | $2,802 | $1,148 | $4,835 |
| Enterprise Value | $7,333 | $8,010 | $8,001 | $5,939 |
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | -$9 | -$16 |
| % Margin | – | – | – | -1,434.8% |
| EBITDA | -$3,192,852 | -$3,234 | -$14,009 | -$208 |
| % Margin | – | – | – | -19,104% |
| Net Income | -$2,474,289 | -$3,579 | -$14,030 | -$356 |
| % Margin | – | – | – | -32,663.7% |
| EPS Diluted | -2.7 | -0.004 | -0.02 | -0.003 |
| % Growth | -69,130.8% | 80.8% | -534.4% | – |
| Operating Cash Flow | -$4,240 | -$1,142 | -$180 | -$136 |
| Capital Expenditures | -$318 | $0 | $0 | $0 |
| Free Cash Flow | -$4,558 | -$1,142 | -$180 | -$136 |